Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer

BMC Genomics

Volumn 11, Issue 1, 2010, Pages

  Pio, Ruben ^a,b   Blanco, David ^a,b   Pajares, Maria J ^a,b   Aibar, Elena ^c   Durany, Olga ^c   Ezponda, Teresa ^a   Agorreta, Jackeline ^a,b   Gomez Roman, Javier ^d   Anton, Miguel A ^e   Rubio, Angel ^e   Lozano, Maria D ^f   López Picazo, Jose M ^f   Subirada, Francesc ^c   Maes, Tamara ^c   Montuenga, Luis M ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e UNIVERSITY OF NAVARRA   (Spain)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CELL CYCLE PROTEIN 6; FOUR AND A HALF LIM DOMAIN PROTEIN 1; ISOPROTEIN; MELANOPHILIN; PROTEIN FHL 1; PROTEIN PCBP4; PROTEIN SUSD2; SUSHI DOMAIN CONTAINING PROTEIN 2; UNCLASSIFIED DRUG; VASCULOTROPIN; MESSENGER RNA;

ALGORITHM; ARTICLE; CALIBRATION; CONTROLLED STUDY; EXON; GENE CONSTRUCT; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MICROARRAY ANALYSIS; MOLECULAR PROBE; VALIDATION STUDY; ALTERNATIVE RNA SPLICING; COLOR; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENETICS; LUNG TUMOR; METHODOLOGY; MOLECULAR CLONING; NUCLEIC ACID HYBRIDIZATION; REPRODUCIBILITY; SACCHAROMYCES CEREVISIAE;

ALGORITHMS; ALTERNATIVE SPLICING; CLONING, MOLECULAR; COLOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; HUMANS; LUNG NEOPLASMS; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SACCHAROMYCES CEREVISIAE;

EID: 77953005066     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-11-352     Document Type: Article

References (62)

1. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456(7221):470-476. 10.1038/nature07509, 2593745, 18978772.
2. Sultan M, Schulz MH, Richard H, Magen A, Klingenhoff A, Scherf M, Seifert M, Borodina T, Soldatov A, Parkhomchuk D, et al. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 2008, 321(5891):956-960. 10.1126/science.1160342, 18599741.
3. Venables JP. Unbalanced alternative splicing and its significance in cancer. Bioessays 2006, 28(4):378-386. 10.1002/bies.20390, 16547952.
4. Kalnina Z, Zayakin P, Silina K, Line A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 2005, 42(4):342-357. 10.1002/gcc.20156, 15648050.
5. Grosso AR, Martins S, Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep 2008, 9(11):1087-1093. 10.1038/embor.2008.189, 2581861, 18846105.
6. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007, 8(4):349-357. 10.1016/S1470-2045(07)70104-3, 17395108.
7. Gattenlohner S, Stuhmer T, Leich E, Reinhard M, Etschmann B, Volker HU, Rosenwald A, Serfling E, Bargou RC, Ertl G, et al. Specific Detection of CD56 (NCAM) Isoforms for the Identification of Aggressive Malignant Neoplasms with Progressive Development. Am J Pathol 2009, 174(4):1160-1171. 10.2353/ajpath.2009.080647, 2671350, 19246644.
8. Calarco JA, Saltzman AL, Ip JY, Blencowe BJ. Technologies for the global discovery and analysis of alternative splicing. Adv Exp Med Biol 2007, 623:64-84. full_text, 18380341.
9. Gardina PJ, Clark TA, Shimada B, Staples MK, Yang Q, Veitch J, Schweitzer A, Awad T, Sugnet C, Dee S, et al. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 2006, 7:325. 10.1186/1471-2164-7-325, 1769375, 17192196.
10. French PJ, Peeters J, Horsman S, Duijm E, Siccama I, van den Bent MJ, Luider TM, Kros JM, van der Spek P, Sillevis Smitt PA. Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. Cancer Res 2007, 67(12):5635-5642. 10.1158/0008-5472.CAN-06-2869, 17575129.
11. Cheung HC, Baggerly KA, Tsavachidis S, Bachinski LL, Neubauer VL, Nixon TJ, Aldape KD, Cote GJ, Krahe R. Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays. BMC Genomics 2008, 9:216. 10.1186/1471-2164-9-216, 2410136, 18474104.
12. Thorsen K, Sorensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, Kruhoffer M, Laurberg S, Borre M, Wang K, et al. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics 2008, 7(7):1214-1224. 10.1074/mcp.M700590-MCP200, 18353764.
13. Xi L, Feber A, Gupta V, Wu M, Bergemann AD, Landreneau RJ, Litle VR, Pennathur A, Luketich JD, Godfrey TE. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res 2008, 36(20):6535-6547. 10.1093/nar/gkn697, 2582617, 18927117.
14. Morgan WR, Ward DC. Three splicing patterns are used to excise the small intron common to all minute virus of mice RNAs. J Virol 1986, 60(3):1170-1174. 253380, 3783817.
15. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996, 14(13):1675-1680. 10.1038/nbt1296-1675, 9634850.
16. Clark TA, Sugnet CW, Ares MJ. Genomewide analysis of mRNA processing in yeast using splicing-specific microarrays. Science 2002, 296(5569):907-910. 10.1126/science.1069415, 11988574.
17. Castle J, Garrett-Engele P, Armour CD, Duenwald SJ, Loerch PM, Meyer MR, Schadt EE, Stoughton R, Parrish ML, Shoemaker DD, et al. Optimization of oligonucleotide arrays and RNA amplification protocols for analysis of transcript structure and alternative splicing. Genome Biol 2003, 4(10):R66. 10.1186/gb-2003-4-10-r66, 328455, 14519201.
18. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos R, Schadt EE, Stoughton R, Shoemaker DD. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003, 302(5653):2141-2144. 10.1126/science.1090100, 14684825.
19. Wang H, Hubbell E, Hu JS, Mei G, Cline M, Lu G, Clark T, Siani-Rose MA, Ares M, Kulp DC, et al. Gene structure-based splice variant deconvolution using a microarray platform. Bioinformatics 2003, 19(Suppl 1):i315-322. 10.1093/bioinformatics/btg1044, 12855476.
20. Anton MA, Gorostiaga D, Guruceaga E, Segura V, Carmona-Saez P, Pascual-Montano A, Pio R, Montuenga LM, Rubio A. SPACE: an algorithm to predict and quantify alternatively spliced isoforms using microarrays. Genome Biol 2008, 9(2):R46. 10.1186/gb-2008-9-2-r46, 2374713, 18312629.
21. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci USA 1990, 87(5):1663-1667. 10.1073/pnas.87.5.1663, 53542, 1689846.
22. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001, 98(24):13790-13795. 10.1073/pnas.191502998, 61120, 11707567.
23. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002, 8(8):816-824.
24. Nguewa PA, Agorreta J, Blanco D, Lozano MD, Gomez-Roman J, Sanchez BA, Valles I, Pajares MJ, Pio R, Rodriguez MJ, et al. Identification of Importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens. BMC Mol Biol 2008, 9:103. 10.1186/1471-2199-9-103, 2612021, 19014639.
25. Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 2006, 6(6):433-446. 10.1038/nri1864, 16724098.
26. Cowling BS, McGrath MJ, Nguyen MA, Cottle DL, Kee AJ, Brown S, Schessl J, Zou Y, Joya J, Bonnemann CG, et al. Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy. J Cell Biol 2008, 183(6):1033-1048. 10.1083/jcb.200804077, 2600747, 19075112.
27. Brown S, McGrath MJ, Ooms LM, Gurung R, Maimone MM, Mitchell CA. Characterization of two isoforms of the skeletal muscle LIM protein 1, SLIM1. Localization of SLIM1 at focal adhesions and the isoform slimmer in the nucleus of myoblasts and cytoplasm of myotubes suggests distinct roles in the cytoskeleton and in nuclear-cytoplasmic communication. J Biol Chem 1999, 274(38):27083-27091. 10.1074/jbc.274.38.27083, 10480922.
28. Lee SM, Li HY, Ng EK, Or SM, Chan KK, Kotaka M, Chim SS, Tsui SK, Waye MM, Fung KP, et al. Characterization of a brain-specific nuclear LIM domain protein (FHL1B) which is an alternatively spliced variant of FHL1. Gene 1999, 237(1):253-263. 10.1016/S0378-1119(99)00251-6, 10524257.
29. Ng EK, Lee SM, Li HY, Ngai SM, Tsui SK, Waye MM, Lee CY, Fung KP. Characterization of tissue-specific LIM domain protein (FHL1C) which is an alternatively spliced isoform of a human LIM-only protein (FHL1). J Cell Biochem 2001, 82(1):1-10. 10.1002/jcb.1110, 11400158.
30. Fryknas M, Wickenberg-Bolin U, Goransson H, Gustafsson MG, Foukakis T, Lee JJ, Landegren U, Hoog A, Larsson C, Grimelius L, et al. Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol 2006, 27(4):211-220. 10.1159/000093056, 16675914.
31. Li X, Jia Z, Shen Y, Ichikawa H, Jarvik J, Nagele RG, Goldberg GS. Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci 2008, 99(7):1326-1333. 10.1111/j.1349-7006.2008.00816.x, 18422756.
32. Sakashita K, Mimori K, Tanaka F, Kamohara Y, Inoue H, Sawada T, Hirakawa K, Mori M. Clinical significance of loss of Fhl1 expression in human gastric cancer. Ann Surg Oncol 2008, 15(8):2293-2300. 10.1245/s10434-008-9904-3, 18465173.
33. Matesic LE, Yip R, Reuss AE, Swing DA, O'Sullivan TN, Fletcher CF, Copeland NG, Jenkins NA. Mutations in Mlph, encoding a member of the Rab effector family, cause the melanosome transport defects observed in leaden mice. Proc Natl Acad Sci USA 2001, 98(18):10238-10243. 10.1073/pnas.181336698, 56945, 11504925.
34. Sugahara T, Yamashita Y, Shinomi M, Yamanoha B, Iseki H, Takeda A, Okazaki Y, Hayashizaki Y, Kawai K, Suemizu H, et al. Isolation of a novel mouse gene, mSVS-1/SUSD2, reversing tumorigenic phenotypes of cancer cells in vitro. Cancer Sci 2007, 98(6):900-908. 10.1111/j.1349-7006.2007.00466.x, 17428258.
35. Fehlbaum P, Guihal C, Bracco L, Cochet O. A microarray configuration to quantify expression levels and relative abundance of splice variants. Nucleic Acids Res 2005, 33(5):e47. 10.1093/nar/gni047, 1064144, 15760843.
36. Hartmann B, Castelo R, Blanchette M, Boue S, Rio DC, Valcarcel J. Global analysis of alternative splicing regulation by insulin and wingless signalling in Drosophila cells. Genome Biol 2009, 10(1):R11. 10.1186/gb-2009-10-1-r11, 2687788, 19178699.
37. Castle JC, Zhang C, Shah JK, Kulkarni AV, Kalsotra A, Cooper TA, Johnson JM. Expression of 24,426 human alternative splicing events and predicted cis regulation in 48 tissues and cell lines. Nat Genet 2008, 40(12):1416-1425. 10.1038/ng.264, 18978788.
38. Rogers S, Cambrosio A. Making a new technology work: the standardization and regulation of microarrays. Yale J Biol Med 2007, 80(4):165-178. 2347363, 18449388.
39. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108. 10.3322/canjclin.55.2.74, 15761078.
40. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2005. 2008, National Cancer Institute Bethesda, MD.
41. Pio R, Montuenga LM. Alternative splicing in lung cancer. J Thorac Oncol 2009, 4(6):674-678. 10.1097/JTO.0b013e3181a520dc, 19461400.
42. Pino I, Pio R, Toledo G, Zabalegui N, Vicent S, Rey N, Lozano MD, Torre W, Garcia-Foncillas J, Montuenga LM. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer 2003, 41(2):131-143. 10.1016/S0169-5002(03)00193-4, 12871776.
43. Zerbe LK, Pino I, Pio R, Cosper PF, Dwyer-Nield LD, Meyer AM, Port JD, Montuenga LM, Malkinson AM. Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing. Mol Carcinog 2004, 41(4):187-196. 10.1002/mc.20053, 15390079.
44. Pio R, Zudaire I, Pino I, Castano Z, Zabalegui N, Vicent S, Garcia-Amigot F, Odero MD, Lozano MD, Garcia-Foncillas J, et al. Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer. Cancer Res 2004, 64(12):4171-4179. 10.1158/0008-5472.CAN-03-2982, 15205328.
45. Laack E, Nikbakht H, Peters A, Kugler C, Jasiewicz Y, Edler L, Brummer J, Schumacher U, Hossfeld DK. Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J Clin Oncol 2002, 20(21):4279-4284. 10.1200/JCO.2002.08.067, 12409325.
46. Sienel W, Dango S, Woelfle U, Morresi-Hauf A, Wagener C, Brummer J, Mutschler W, Passlick B, Pantel K. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. Clin Cancer Res 2003, 9(6):2260-2266.
47. Lee MK, Kim JH, Lee CH, Kim JM, Kang CD, Kim YD, Choi KU, Kim HW, Kim JY, Park do Y, et al. Clinicopathological significance of BGP expression in non-small-cell lung carcinoma: relationship with histological type, microvessel density and patients' survival. Pathology 2006, 38(6):555-560. 10.1080/00313020601024029, 17393985.
48. Estrera VT, Luo W, Phan D, Earley K, Hixson DC, Lin SH. The cytoplasmic domain of C-CAM1 tumor suppressor is necessary and sufficient for suppressing the tumorigenicity of prostate cancer cells. Biochem Biophys Res Commun 1999, 263(3):797-803. 10.1006/bbrc.1999.1443, 10512760.
49. Wang L, Lin SH, Wu WG, Kemp BL, Walsh GL, Hong WK, Mao L. C-CAM1, a candidate tumor suppressor gene, is abnormally expressed in primary lung cancers. Clin Cancer Res 2000, 6(8):2988-2993.
50. Fimia GM, De Cesare D, Sassone-Corsi P. A family of LIM-only transcriptional coactivators: tissue-specific expression and selective activation of CREB and CREM. Mol Cell Biol 2000, 20(22):8613-8622. 10.1128/MCB.20.22.8613-8622.2000, 102166, 11046156.
51. Arber S, Halder G, Caroni P. Muscle LIM protein, a novel essential regulator of myogenesis, promotes myogenic differentiation. Cell 1994, 79(2):221-231. 10.1016/0092-8674(94)90192-9, 7954791.
52. Kadrmas JL, Beckerle MC. The LIM domain: from the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol 2004, 5(11):920-931. 10.1038/nrm1499, 15520811.
53. Ding L, Wang Z, Yan J, Yang X, Liu A, Qiu W, Zhu J, Han J, Zhang H, Lin J, et al. Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway. J Clin Invest 2009, 119(2):349-361. 2631293, 19139564.
54. Kwapiszewska G, Wygrecka M, Marsh LM, Schmitt S, Trosser R, Wilhelm J, Helmus K, Eul B, Zakrzewicz A, Ghofrani HA, et al. Fhl-1, a new key protein in pulmonary hypertension. Circulation 2008, 118(11):1183-1194. 10.1161/CIRCULATIONAHA.107.761916, 18725486.
55. Liang L, Zhang HW, Liang J, Niu XL, Zhang SZ, Feng L, Liang YM, Han H. KyoT3, an isoform of murine FHL1, associates with the transcription factor RBP-J and represses the RBP-J-mediated transactivation. Biochim Biophys Acta 2008, 1779(12):805-810.
56. Hu XB, Feng F, Wang YC, Wang L, He F, Dou GR, Liang L, Zhang HW, Liang YM, Han H. Blockade of Notch signaling in tumor-bearing mice may lead to tumor regression, progression, or metastasis, depending on tumor cell types. Neoplasia 2009, 11(1):32-38. 2606116, 19107229.
57. Fukuda M, Kuroda TS, Mikoshiba K. Slac2-a/melanophilin, the missing link between Rab27 and myosin Va: implications of a tripartite protein complex for melanosome transport. J Biol Chem 2002, 277(14):12432-12436. 10.1074/jbc.C200005200, 11856727.
58. Strom M, Hume AN, Tarafder AK, Barkagianni E, Seabra MC. A family of Rab27-binding proteins. Melanophilin links Rab27a and myosin Va function in melanosome transport. J Biol Chem 2002, 277(28):25423-25430. 10.1074/jbc.M202574200, 11980908.
59. Martel JA, Michael D, Fejes-Toth G, Naray-Fejes-Toth A. Melanophilin, a novel aldosterone-induced gene in mouse cortical collecting duct cells. Am J Physiol Renal Physiol 2007, 293(3):F904-913. 10.1152/ajprenal.00365.2006, 17609287.
60. Sugahara T, Yamashita Y, Shinomi M, Isobe Y, Yamanoha B, Iseki H, Takeda A, Okazaki Y, Kawai K, Suemizu H, et al. von Willebrand factor type D domain mutant of SVS-1/SUSD2, vWD(m), induces apoptosis in HeLa cells. Cancer Sci 2007, 98(6):909-915. 10.1111/j.1349-7006.2007.00467.x, 17428257.
61. Kim E, Goren A, Ast G. Insights into the connection between cancer and alternative splicing. Trends Genet 2008, 24(1):7-10. 10.1016/j.tig.2007.10.001, 18054115.
62. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991, 266(18):11947-11954.